CPC C07K 16/2896 (2013.01) [A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6817 (2017.08); A61K 47/6849 (2017.08); C07K 16/2803 (2013.01); C12N 9/2497 (2013.01); G01N 33/573 (2013.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/30 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); G01N 2333/912 (2013.01)] | 20 Claims |
1. A method for treating or managing rheumatoid arthritis, inflammatory bowel disease, asthma, allergic inflammation, a gastrointestinal disorder or mastocytosis, the method comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof, which immunospecifically binds to human KIT and comprises:
(i) a variable light (“VL”) chain region comprising a VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22, respectively; and
(ii) a variable heavy (“VH”) chain region comprising a VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25, respectively.
|